戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 lishment of hypoxia, metronidazole showed no antituberculous activity in this in vivo hypoxic granulo
2         The anaerobic drug metronidazole has antituberculous activity under hypoxic conditions in vit
3 trophils contain antimicrobial peptides with antituberculous activity, but their contribution to immu
4 entify new antimicrobial drugs with specific antituberculous activity.
5 ween two distinct models of human macrophage antituberculous activity: primary infection of naive mac
6 bility of M. tuberculosis to four first-line antituberculous agents demonstrated equivalent interpret
7  hepatotoxicity was observed with first line antituberculous agents using four drug standard inductio
8                      In animals treated with antituberculous antibiotics only, the inflammation and l
9                                   Other than antituberculous chemotherapy and masks, there are few me
10                                   Successful antituberculous chemotherapy resulted in a 50% reduction
11                                              Antituberculous chemotherapy was associated with surviva
12 hese agents may be considered as adjuncts to antituberculous chemotherapy, and may be particularly us
13  with treatment failure or relapse following antituberculous chemotherapy.
14 ive animals, allowing accurate evaluation of antituberculous drug efficacy.
15 erculosis gene expression in response to the antituberculous drug isoniazid.
16 osynthetic pathway is a well known source of antituberculous drug targets.
17 ared genes included target genes of existing antituberculous drugs including SQ109, which targets the
18 traditional view that acquired resistance to antituberculous drugs is driven by poor compliance and p
19 n cases) had isolates resistant to 1 or more antituberculous drugs, and 3 (19% of all Tibetan cases)
20 e-bound structure, we suggest a new class of antituberculous drugs, made by connecting two trehalose
21    Given the low potency of many second-line antituberculous drugs, we hypothesized that an aggressiv
22 cular testing does not yield results for all antituberculous drugs.
23  pathway is one of the targets of first-line antituberculous drugs.
24 tory therapeutics and compounds that enhance antituberculous immunity.
25 isoniazid alone or in combination with other antituberculous medications.
26 atient was originally started on a four-drug antituberculous regimen of isoniazid, rifampin, ethambut
27 rt-course chemotherapy with standard Russian antituberculous regimens.
28 with otherwise unexplained uveitis completed antituberculous therapy (29/710; 4% of all included pati
29 rculous symptomatology and lesions following antituberculous therapy (paradoxical response) has previ
30 tients with AIDS and TB who are treated with antituberculous therapy and subsequently with combinatio
31 ransferases are highly promising targets for antituberculous therapy by using antisense or other anti
32 ogical immunomodulatory compounds to enhance antituberculous therapy has been hampered by the limited
33 he myocardium, and we believe that effective antituberculous therapy has led to resolution of the GCM
34 n Africa, including consideration of empiric antituberculous therapy in individuals living with HIV,
35 trategy for monitoring liver function during antituberculous therapy is unclear.
36 mechanisms are poorly defined and no current antituberculous therapy reduces host tissue damage.
37               Patients known to have been on antituberculous therapy were excluded from the analysis.
38  for a minimum of 1 year after completion of antituberculous therapy where indicated.
39  credible interval, 0.05-0.49 for receipt of antituberculous therapy).
40 spite a generally good response to effective antituberculous therapy, the prognosis remains poor.
41 e uveitis cause had a beneficial response to antituberculous therapy.
42 N)-gamma remain low even after completion of antituberculous therapy.
43 sults after completing a standard regimen of antituberculous treatment (ATT), with some patients havi
44                               Median time on antituberculous treatment for patients with spinal and o
45  positive early in the course of efficacious antituberculous treatment, we predict that both breath a
46 ting systemic corticosteroids in addition to antituberculous treatment.